Skip to main content
SpringerLink
Log in

Maligne Hodentumore: Nachsorge

  • Living reference work entry
  • First Online:
Uroonkologie

Part of the book series: Springer Reference Medizin ((SRM))

  • 166 Accesses

Zusammenfassung

In den vergangenen Jahren konnte ein Konsens für die Nachsorge von Patienten mit Hodentumoren definiert werden. Die Frequenz und Modalität der Nachsorge wird aufgrund der Histologie, des initalen Tumorstadiums sowie der durchgeführten Behandlung festgelegt. Berücksichtigt wird dabei das jeweilige Rezidivrisiko und die häufigste Rezidivlokalisation. Es können drei Hauptgruppen definiert werden: 1. Seminom Stadium I (unabhängig vom gewählten Management); 2. Nichtseminom Stadium I mit Surveillance; 3. Alle anderen Patienten mit kurativer Therapie und kompletter Remission. Die tumorspezifische Nachsorge wird für fünf Jahre vorgenommen. Danach soll eine lebenslange Nachsorge zur Erfassung und Behandlung von Spättoxizitäten mit Kontrollen beim Grundversorger alle 1–2 Jahre durchgeführt werden. Der Einbezug des Patienten mit Stärkung der Eigenverantwortung und somit Verbesserung der Adhärenz in der Nachsorge ist wichtig.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Literatur

  • Abouassaly R, Fosså SD, Giwercman A, Kollmannsberger C, Motzer RJ, Schmoll HJ, Sternberg CN (2011) Sequelae of treatment in long-term survivors of testis cancer. Eur Urol 60:516–526

    Article  Google Scholar 

  • Albers P, Siener R, Krege S, Schmelz HU, Dieckmann KP, Heidenreich A, Kwasny P, Pechoel M, Lehmann J, Kliesch S, Köhrmann KU, Fimmers R, Wessbach L, Loy V, Wittekind C, Hartmann M (2008) Randomized phase III trial comparing tetroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapie in the adjuvant treatment of stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol 26(18):2966–2972

    Article  CAS  Google Scholar 

  • Albers P, Albrecht W, Algaba F et al (2018) EAU guidelines on testicular cancer. https://uroweb.org/guideline/prostate-cancer/. Zugegriffen am 06.07.2018

  • Beyer J, Albers P, Altena R et al (2013) Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ- cell cancer. Ann Oncol 24(4):878–888

    Article  CAS  Google Scholar 

  • Cathomas R, Hartmann M, Krege S, Souchon R, Lorch A, Mayer F, De Santis M, Gillessen S (2011) Interdisciplinary evidence-based recommendations for the follow-up of testicular germ cell cancer Patients. Onkologie 34:59–64

    PubMed  Google Scholar 

  • Classen J, Schmidberger H, Meisner C, Souchon R, Sautter-Bihl ML, Sauer R, Weinknecht S, Köhrmann U, Bamberger M (2003) Radiotherapy for stage IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol 21(6):1101–1106

    Article  Google Scholar 

  • De Wit R, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM, Fosså SD, Cook P, de Prijck L, Stenning S, Collette L (2001) Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatnment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 19(6):1629–1640

    Article  Google Scholar 

  • Fosså SD (2004) Long-term sequelae after cancer therapy. Acta Oncol 43(2):134–141

    Article  Google Scholar 

  • Gietema JA, Meinardi T, Sleijfer DT, Hoekstra HJ, van der Graaf WTA (2002) Routine chest X-rays have no additional value in the detection of relapse during routine follow-up of patients treated with chemotherapie for disseminated nonseminomatous testicular cancer. Ann Oncol 13:1616–1620

    Article  CAS  Google Scholar 

  • Hartmann M, Krege S, Souchon R, De Santis M, Gillessen S, Cathomas R (2011) Nachsorge von Hodentumoren. Interdisziplinäre evidenzbasierte Empfehlungen. Urologe 50:830–835

    Article  CAS  Google Scholar 

  • Harvey ML, Geldart TR, Duell R, Mead GM, Tung K (2002) Routine computerised tomo- graphic scans of the thorax in surveillance in stage I testicular non-seminomatous germ- cell cancer – a necessary risk? Ann Oncol 13:237–242

    Article  CAS  Google Scholar 

  • Haugnes HS, Bosl GJ, Boer H, Gietema JA, Brydoy M, Oldenburg J, Dahl AA, Bremnes RM, Fosså SD (2012) Long-term and late effects of germ cell testicular cancer treatment and implications for follw-up. J Clin Oncol 30:3752–3763

    Article  Google Scholar 

  • Honecker F, Aparicio J, Berney D et al (2018) ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Ann Oncol 29:1658–1686

    Article  CAS  Google Scholar 

  • International Germ Cell Consensus Classification (1997) A prognostic factor-based staging system for metastatic germ cell cancer – International Germ Cell Cancer Collaborative Group. J Clin Oncol 15:594–603

    Article  Google Scholar 

  • Kollmannsberger C, Tandstad T, Bedard PL et al (2015) Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J Clin Oncol 33:51–57

    Article  Google Scholar 

  • Kondagunta GV, Motzer RJ (2006) Chemotherapy for advanced germ cell tumors. J Clin Oncol 24:5493–5502

    Article  CAS  Google Scholar 

  • Krege S, Beyer J, Souchon R, Albers P, Albrecht E et al (2008) European Consensus Conference on diagnosis and treatment of germ cell cancer: a report oft he second meeting oft the European Germ Cell Cancer Consensus Group (EGCCCG). Part I and II. Eur Urol 53:478–513

    Article  Google Scholar 

  • Lauritsen J, Kier MG, Mortensen MS et al (2015) Germ cell cancer and multiple relapses: toxicity and survival. J Clin Oncol 33:3116–3123

    Article  CAS  Google Scholar 

  • Martin JM, Panzarelli T, Zwahlen DR, Chung P, Warde P (2007) Evidence-based guidelines for following stage I seminoma. Cancer 109:2248–2256

    Article  Google Scholar 

  • Mead GM, Fossa SD, Oliver TD et al (2011) Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up. J Natl Cancer Inst 103:241–249

    Article  Google Scholar 

  • Mettler FA, Walter H, Terry T, Mahadevappa M (2008) Effective doses in radiology and diagnostic nuclear medicine: a catalog. Radiology 248:254–263

    Article  Google Scholar 

  • Mezvrishvili Z, Tchanturaia Z, Toidze T, Turmanidze N, Kekelidze M, Managadze L (2007) Is ultrasound of the retroperitoneum a valuable staging method in selecting testicular cancer patients for primary lymph node dissection? Urol Int 78:226–229

    Article  Google Scholar 

  • Mortensen MS, Lauritsen J, Gundgaard MG et al (2014) A nationwide cohort study of stage I seminoma patients followed on a surveillance program. Eur Urol 66:1172–1178

    Article  Google Scholar 

  • Mortensen MS, Lauritsen J, Kier MG et al (2016) Late relapses in stage I testicular cancer patients on surveillance. Eur Urol 70:365–371

    Article  Google Scholar 

  • Mykletun A, Dahl AA, Haaland CF et al (2005) Side effects and cancer-related stress determine quality of life in long-term survivors of testicular cancer. J Clin Oncol 23:3061–3068

    Article  Google Scholar 

  • Nord C, Bjoro T, Ellingsen D et al (2003) Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol 44:322–328

    Article  Google Scholar 

  • Oldenburg J, Alfsen GC, Waehre H, Fosså SD (2006) Late recurrences of germ cell malignancies: a population-based experience over three decades. Br J Cancer 94:820–827

    Article  CAS  Google Scholar 

  • Oliver RT, Mead GM, Rustin GJ, Joffe JK, Aass N, Coleman R, Gabe R, Pollock P, Srenning SP (2011) Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC3098 study (ISRCTN27163214). J Clin Oncol 29(8):957–962

    Article  CAS  Google Scholar 

  • Richiardi L, Scelo G, Bofetta B et al (2007) Second malignancies among survivors of germ-cell testicular cancer: a pooled analysis between 13 cancer registries. Int J Cancer 120:623–631

    Article  CAS  Google Scholar 

  • Rossen PB, Pedersen AF, Zachariae R, von der Maase H (2009) Health-related quality of life in long-term survivors of testicular cancer. J Clin Oncol 27:5993–5999

    Article  Google Scholar 

  • Rustin GJ, Mead GM, Sally P et al (2007) Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197- The National Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol 10:1310–1315

    Article  Google Scholar 

  • Smith AB, Butow P, Olver I et al (2016) The prevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study. J Cancer Surviv 10:223–233

    Article  Google Scholar 

  • Souchon R, Hartmann M, Krege S, Lorch A, Mayer F, De Santis M, Gillessen S, Beyer J, Cathomas R (2011) Interdisciplinary ecidence-based recommendations for the follow up of early stage seminomatous testicular germ cell cancer patients. Strahlenther Onkol 187(3):158–166

    Article  Google Scholar 

  • Tandstad T, Ståhl O, Håkansson U et al (2014) One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group. Ann Oncol 25:2167–2172

    Article  CAS  Google Scholar 

  • Tandstad T, Ståhl O, Dahl O et al (2016) Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). Ann Oncol 27:1299–1304

    Article  CAS  Google Scholar 

  • Tarin TV, Sonn G, Shingal R (2009) Estimating the risk of cancer associated with imaging related radiation during surveillance for stage I testicular cancer using computerrized tomography. J Urol 181(2):627–632

    Article  Google Scholar 

  • Travis LB, Fosså SD, Schonfeld SJ McMaster ML, Lynch CF, Storm H, Hall P, Holowaty E, Andersen A, Pukkala E, Andersson A, Kaijser M, Gospodarowicz M, Joensuu T, cohen RJ, Boice JD Jr, Dores GM, Gilbert ES (2005) Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Inst 97(18):1354–1365

    Article  Google Scholar 

  • Travis BL, Beard C, Allan JM, Dahl AA, Feldmann DR, Oldenburg J et al (2010) Testicular cancer survivorship: research and recommendations. J Natl Cancer Inst 102(15):1114–1130

    Article  Google Scholar 

  • Trigo JM, Tabernero IM, Paz-Ares J, Garcia-Liano IL, Mora J, Lianes P, Esteban E, Salvador R, Lopez-Lopez JJ, Corte-Funes H (2001) Tumor markers at the time of recurrence in patients with germ cell tumors. Cancer 88:162–168

    Article  Google Scholar 

  • TRISST( MRC TE24) trial of imaging and schedule in seminoma testis. www.ctu.mrc.ac.uk/studies/TE24.asp

  • Warde P, Gospodarowicz MK, Bannerjee D et al (1997) Prognostic factors for relapse in stage I testicular seminoma treated with surveillance. J Urol 157:1705–1710

    Article  CAS  Google Scholar 

  • White PM, Howard GCW, Best JJK, Wriht AR (1997) The role of computed tomographic examination of the pelvis in the management of testicular germ cell tumors. Clin Radiol 52:124–129

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung für Onkologie/Hämatologie, Kantonsspital Graubünden, Chur, Schweiz

    Richard Cathomas

  2. Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Urologie, Hamburg, Deutschland

    Michael Hartmann

  3. Klinik für Urologie, Kinderurologie und urologische Onkologie, Kliniken Essen Mitte, Hyussens-Stiftung, Essen, Deutschland

    Susanne Krege

Authors
  1. Richard Cathomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Hartmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Susanne Krege
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard Cathomas .

Editor information

Editors and Affiliations

  1. Helios Marien Klinikum Duisburg, Duisburg, Nordrhein-Westfalen, Germany

    Herbert Rübben

  2. Urologische Klinik/Poliklinik, Universitätsklinikum Rostock, Rostock, Mecklenburg-Vorpommern, Germany

    Oliver Hakenberg

  3. Klinik und Poliklinik für Urologie , Universitätsklinikum Jena, Jena, Thüringen, Germany

    Marc-Oliver Grimm

  4. Caritaskrankenhaus St. Josef, Regensburg, Germany

    Maximilian Burger

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Cathomas, R., Hartmann, M., Krege, S. (2019). Maligne Hodentumore: Nachsorge. In: Rübben, H., Hakenberg, O., Grimm, MO., Burger, M. (eds) Uroonkologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-54652-9_71-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-54652-9_71-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-54652-9

  • Online ISBN: 978-3-662-54652-9

  • eBook Packages: Springer Referenz Medizin

Publish with us

Policies and ethics

Search

Navigation